Enrollment
Item
enrolled on protocol ibcsg-1-98
boolean
C1516879 (UMLS CUI [1])
Tamoxifen | letrozole | Additional Therapy Expected
Item
currently receiving (i.e., have not yet completed) 5 years of treatment with tamoxifen or letrozole and expected to receive ≥ 6 months of additional treatment on protocol ibcsg-1-98
boolean
C0039286 (UMLS CUI [1])
C0246421 (UMLS CUI [2])
C1706712 (UMLS CUI [3,1])
C1517001 (UMLS CUI [3,2])
Breast cancer recurrent | Second Primary Cancers
Item
no recurrent breast cancer or second primary cancer
boolean
C0278493 (UMLS CUI [1])
C0751623 (UMLS CUI [2])
Bone Diseases | Osteomalacia | Osteogenesis Imperfecta
Item
no known bone disease (including osteomalacia or osteogenesis imperfecta)
boolean
C0005940 (UMLS CUI [1])
C0029442 (UMLS CUI [2])
C0029434 (UMLS CUI [3])
Hormone Receptor Status
Item
hormone receptor status
boolean
C0019929 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
Estrogen receptor positive tumor | Progesterone receptor positive tumor
Item
estrogen and/or progesterone receptor positive tumor
boolean
C1562312 (UMLS CUI [1])
C1562928 (UMLS CUI [2])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Gender
Item
female
boolean
C0079399 (UMLS CUI [1])
Postmenopausal state
Item
postmenopausal
boolean
C0232970 (UMLS CUI [1])
Thyroid Disease Uncontrolled | Parathyroid Disease Uncontrolled | Cushing's disease | Pituitary Diseases
Item
no uncontrolled thyroid or parathyroid disease, cushing's disease, or other pituitary diseases
boolean
C0040128 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0030517 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0221406 (UMLS CUI [3])
C0032002 (UMLS CUI [4])
Malabsorption Syndrome | Vitamin D Deficiency Relevant Clinical
Item
no malabsorption syndrome or clinically relevant vitamin d deficiency
boolean
C0024523 (UMLS CUI [1])
C0042870 (UMLS CUI [2,1])
C2347946 (UMLS CUI [2,2])
C0205210 (UMLS CUI [2,3])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
disease characteristic
Item
see disease characteristics
boolean
C0599878 (UMLS CUI [1])
Anticonvulsants
Item
more than 1 year since prior and no concurrent anticonvulsants
boolean
C0003286 (UMLS CUI [1])
Adrenal Cortex Hormones Dose | Prednisone U/day
Item
more than 6 months since prior and no concurrent corticosteroids at doses > the equivalent of 5 mg/day of prednisone for > 2 weeks total
boolean
C0001617 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0032952 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
Sodium Fluoride Dose U/day
Item
no prior or concurrent sodium fluoride at daily doses ≥ 5 mg/day for > 1 month
boolean
C0037508 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
Anabolic steroids
Item
more than 12 months since prior and no concurrent anabolic steroids
boolean
C0002744 (UMLS CUI [1])
Pharmaceutical Preparations Prevention Osteoporosis | Calcium | Cholecalciferol | Vitamin D
Item
more than 6 months since any prior drug for the prevention of osteoporosis (excluding calcium or cholecalciferol [vitamin d])
boolean
C0013227 (UMLS CUI [1,1])
C2700409 (UMLS CUI [1,2])
C0029456 (UMLS CUI [1,3])
C0006675 (UMLS CUI [2])
C0008318 (UMLS CUI [3])
C0042866 (UMLS CUI [4])
Warfarin
Item
concurrent warfarin allowed provided duration of treatment is no more than 4 weeks
boolean
C0043031 (UMLS CUI [1])